Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC)

Archives of Gerontology and Geriatrics

Volumn 55, Issue 2, 2012, Pages 271-275

  Berretta, Massimiliano ^a   Zanet, Ernesto ^a,b   Nasti, Guglielmo ^c   Lleshi, Arben ^a   Frustaci, Sergio ^a   Fiorica, Francesco ^d   Bearz, Alessandra ^a   Talamini, Renato ^a   Lestuzzi, Chiara ^a   Lazzarini, Renzo ^a   Fisichella, Rossella ^b   Cannizzaro, Renato ^a   Iaffaioli, Rosario Vincenzo ^c   Berretta, Salvatore ^b   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Cancer therapy in elderly; Colorectal cancer; Metastatic cancer; Oxaliplatin

Indexed keywords

ANTIEMETIC AGENT; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84864959882     PISSN: 01674943     EISSN: 18726976     Source Type: Journal    
DOI: 10.1016/j.archger.2011.08.016     Document Type: Article

References (39)

1. André T., Bensmaine M.A., Louvet C., Francois E., Lucas V., Desseigne F., Beerblock K., Bouché O., Carola E., Merrouche Y., Morvan F., Dupont-André G., De Gramont A. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin. Oncol. 1999, 17:3560-3568.
2. André T., Louvet C., Raymond E., Tournigand C., De Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol. 1998, 9:1251-1253.
3. Armitage P., Berry G. Statistical Methods in Medical Research 1987, Blackwell Sci. Publication, London.
4. Au H.J., Mulder K.E., Fields A.L. Systematic review of management of colorectal cancer in elderly patients. Clin. Colorectal Cancer 2003, 3:165-171.
5. Berardi R., Saladino T., Mari D., Silva R.R., Scartozzi M., Verdecchia L., Onofri A., Cascinu S. Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy. Tumori 2005, 91:463-466.
6. Berretta M., Bearz A., Frustaci S., Talamini R., Lombardi D., Fratino L., Lleshi A., Bonanno S., Spartà D., Palmucci S., Berretta S., Tirelli U. Folfox2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients. J. Chemother. 2008, 20:503-508.
7. Berretta M., Cappellani A., Fiorica F., Nasti G., Frustaci S., Fisichella R., Bearz A., Talamini R., Lleshi A., Tambaro R., Cocciolo A., Ristagno M., Bolognese A., Basile F., Meneguzzo N., Berretta S., Tirelli U. Folfox4 in the treatment of metastatic colorectal cancer in elderly patients: a prospective study. Arch. Gerontol. Geriatr. 2011, 52:89-93.
8. Chiara S., Nobile M.T., Vincenti M., Lionetto R., Gozza A., Barzacchi M.C., Sanguineti O., Repetto L., Rosso R. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother. Pharmacol. 1998, 42:336-340.
9. Comella P., Natale D., Farris A., Gambardella A., Maiorino L., Massidda B., Casaretti R., Tafuto S., Lorusso V., Leo S., Cannone M. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005, 104:282-289.
10. De Gramont A., Figer M., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., De Braud F., Wilson C., Morvan F., Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18:2938-2947.
11. De Gramont A., Vignoud J., Tournigand C., Louvet C., André T., Varette C., Raymond E., Moreau S., Le Bail N., Krulik M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 1997, 33:214-219.
12. Extermann M., Albrand G., Chen H., Zanetta S., Schonwetter R., Zulian G.B., Cantor A., Droz J.P. Are older French patients as willing as older American patients to undertake chemotherapy?. J. Clin. Oncol. 2003, 21:3214-3219.
13. Feliu J., Escudero P., Llosa F., Bolaños M., Vicent J.M., Yubero A., Sanz-Lacalle J.J., Lopez R., Lopez-Gómez L., Casado E., Gómez-Reina M.J., González-Baron M. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group Study. J. Clin. Oncol. 2005, 23:3104-3111.
14. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007, 18:581-592.
15. Figer A., Perez-Staub N., Carola E., Tourningard C., Lledo G., Flesh M., Barcelo R., Cervantes A., André T., Colin P., Louvet C., De Gramont A. Folfox in patients aged between 75 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007, 110:2666-2671.
16. Folprecht G., Cunningham D., Ross P., Glimelius B., Di Costanzo F., Wils J., Scheithauer W., Rougier P., Aranda E., Hecker H., Köhne C.H. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann. Oncol. 2004, 15:1330-1338.
17. Folprecht G., Seymour M.T., Saltz L., Douillard J.Y., Hecker H., Stephens R.J., Maughan T.S., Van Cutsem E., Rougier P., Mitry E., Schubert U., Köhne C.H. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J. Clin. Oncol. 2008, 26:1443-1451.
18. Gatta G., Faivre J., Capocaccia R., Ponz de Leon M. Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur. J. Cancer 1998, 34:2176-2183.
19. Goldberg R.M., Tabah-Fisch I., Bleiberg H., De Gramont A., Tournigand C., André T., Rothenberg M.L., Green E., Sargent D.J. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J. Clin. Oncol. 2006, 24:4085-4091.
20. Hill C., Doyon F. The frequency of cancer in France: all ages and under age 15, mortality in 2003 and trends since 1968. Bull. Cancer 2007, 94:7-13.
21. Honecker F., Köhne C.H., Bokemeyer C. Colorectal cancer in the elderly: is palliative chemotherapy of value?. Drugs Aging 2003, 20:1-11.
22. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53:457-481.
23. Kim J.H., Oh D.Y., Kim Y.J., Han S.W., Choi I.S., Kim D.W., Im S.A., Kim T.Y., Lee J.S., Heo D.S., Bang Y.J., Kim N.K. Reduced dose intensity Folfox-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. J. Korean Med. Sci. 2005, 20:806-810.
24. Köhne C.H., Cunningham D., Di C.F., Glimelius B., Blijham G., Aranda E., Scheithauer W., Rougier P., Palmer M., Wils J., Baron B., Pignatti F., Schöffski P., Micheel S., Hecker H. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann. Oncol. 2002, 13:308-317.
25. Mahoney T., Kuo Y.H., Topilow A., Davis J.M. Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch. Surg. 2000, 135:182-185.
26. Maindrault-Goebel F., Louvet C., André T., Carola E., Lotz J.P., Molitor J.L., Garcia M.L., Gilles-Amar V., Izrael V., Krulik M., De Gramont A. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur. J. Cancer 1999, 35:1338-1342.
27. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966, 50:163-170.
28. Mattioli R., Massacesi C., Recchia F., Marcucci F., Cappelletti C., Imperatori L., Pilone A., Rocchi M., Cesta A., Laici G., Bonsignori M., Lippe P. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann. Oncol. 2005, 16:1147-1151.
29. Popescu R.A., Norman A., Ross P.J., Parikh B., Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Clin. Oncol. 1999, 17:2412-2418.
30. Power D.G., Lichtman S.M. Chemotherapy for the elderly patient with colorectal cancer. Cancer J. 2010, 16:241-252.
31. Raymond E., Chaney S.G., Taamma A., Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol. 1998, 9:1053-1071.
32. Rosati G., Cordio S. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer. Tumori 2006, 92:290-294.
33. Rosati G., Cordio S., Bordonaro R., Caputo G., Novello G., Reggiardo G., Manzione L. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann. Oncol. 2009, 21:781-786.
34. Sastre J., Aranda E., Massuti B., Tabernero J., Chaves M., Abad A., Carrato A., Reina J.J., Queralt B., Gomez-Espana A., Gonzalez-Flores E., Rivera F., Losa F., Garcia T., Sanchez-Rovira P., Maestu I., Diaz-Rubio E. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit. Rev. Oncol. Hematol. 2009, 70:134-144.
35. Sastre J., Marcuello E., Masutti B., Navarro M., Gil S., Antòn A., Abad A., Aranda E., Maruel J., Valladares M., Maestu I., Carrato A., Vincent J.M., Diaz-Rubio E. Irinotecan in combination with fluorouracil in a 48-hour continuos infusion as first line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. J. Clin. Oncol. 2005, 23:3545-3551. Cooperative Group for the Treatment of Digestive Tumors.
36. Schrag D., Cramer L.D., Bach P.B., Begg C.B. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J. Natl. Cancer Inst. 2001, 93:850-857.
37. Stein B.N., Petrelli N.J., Douglass H.O., Driscoll D.L., Arcangeli G., Meropol N.J. Age and sex are independent predictors of 5-fluorouracil toxicity: analyses of a large scale phase II trial. Cancer 1995, 75:11-17.
38. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., Van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92:205-216.
39. Tournigand C., Cervantes A., Figer A., Lledo G., Flesch M., Buyse M., Mineur L., Carola E., Etienne P.L., Rivera F., Chirivella I., Perez-Staub N., Louvet C., André T., Tabah-Fisch I., de Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J. Clin. Oncol. 2006, 24:394-400.